thiophenes has been researched along with Histiocytosis, Langerhans-Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aleem, E; Arceci, RJ; Azorsa, DO; Bista, R; Henry, MM; Lee, DW; Patel, AR; Wai, DH | 1 |
| Allen, CE; Arceci, RJ; Cornfeld, M; Dunkel, IJ; Heaney, ML; Jacobsen, E; McClain, K; Morris, SR; Murnane, A; Noble, R; Portnoy, A; Reedy, BA; Rodriguez-Galindo, C; Smith, DA; Vaiselbuh, S; Vassallo, R; Whitlock, J | 1 |
1 trial(s) available for thiophenes and Histiocytosis, Langerhans-Cell
| Article | Year |
|---|---|
A phase IIa study of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis.
Topics: Adult; Aged; Antineoplastic Agents; Female; Hematologic Neoplasms; Histiocytosis, Langerhans-Cell; Humans; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyrazoles; Thiophenes; Treatment Outcome; United States | 2017 |
1 other study(ies) available for thiophenes and Histiocytosis, Langerhans-Cell
| Article | Year |
|---|---|
Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.
Topics: Adolescent; Adrenal Cortex Hormones; Butadienes; Combined Modality Therapy; Cytarabine; Disease Progression; Drug Resistance; Drug Therapy, Combination; Enzyme Activation; Exons; HEK293 Cells; Hematopoietic Stem Cell Transplantation; Histiocytosis, Langerhans-Cell; Humans; Male; MAP Kinase Kinase 1; MAP Kinase Signaling System; Molecular Targeted Therapy; Mutation; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazoles; Pyridones; Pyrimidinones; Recombinant Fusion Proteins; Sequence Deletion; Thiophenes; Vincristine | 2018 |